actually viewed by unauthorized persons.

Case 9: Three attorneys prepared and filed the public version of a brief that contained bracketed but unredacted BPI and served copies of the brief to parties on the public service list and to other non-authorized persons. The Commission found that these attorneys breached the APO and decided to issue a warning letter to each of the attorneys. (The Commission also found that two other attorneys whose name appeared on the brief did not breach the APO because they did not assist in the preparation of the public version of the brief at issue). In making its decision, the Commission noted that the breach was inadvertent; the attorneys had not previously breached an APO; they took immediate action to mitigate the harm; they immediately reported the potential breach to the Commission; and it did not appear that the BPI was actually read by any unauthorized persons.

IV. Specific Investigations in Which No Breach Was Found

As noted above, in three investigations where the Commission found a breach by one or more parties, it also found that one or more parties investigated did not breach the APO. In addition, the Commission completed one investigation in 1996 in which it found that no breach by any party had occurred. In that investigation, the Commission reached its conclusion on the basis of a finding that the BPI in question, which was petitioner's BPI, had previously been publicly disclosed by the petitioners.

V. Investigations of Breaches Other Than in Antidumping or Countervailing Duty Proceedings

In 1996, the Commission conducted one investigation of an alleged breach of an APO in a proceeding brought pursuant to Section 201 of the Trade Act of 1974. In that investigation, an APO signatory sent the proprietary version of a brief to a party on the public service list that was not a party to the APO. The Commission found that the signatory breached the APO. In deciding to issue only a warning letter, the Commission pointed to the following factors: the breach was inadvertent; the signatory had not previously breached an APO; the signatory took actions to mitigate any harm by retrieving the unopened envelope containing the brief; and thus it did not appear that any unauthorized persons viewed the BPI.

During 1996, the Commission did not conduct any investigations of breaches of APOs in proceedings filed under Section 337 of the Tariff Act of 1930.

By order of the Commission.

Issued: March 13, 1997.

Donna R. Koehnke,

Secretary.

[FR Doc. 97–6904 Filed 3–18–97; 8:45 am]

BILLING CODE 7020–02–P

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: United States International Trade Commission.

TIME AND DATE: March 28, 1997 at 11:00 a.m.

PLACE: Room 101, 500 E Street S.W., Washington, DC 20436.

STATUS: Open to the public.

MATTERS TO BE CONSIDERED:

1. Agenda for future meeting.
2. Minutes.
3. Ratification List.
4. Inv. No. 731–TA–760 (Preliminary) (Needle Bearing Wire from Japan)—briefing and vote.
5. Outstanding action jackets: none

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

Issued: March 13, 1997.

By order of the Commission:

Donna R. Koehnke,

Secretary.

[FR Doc. 97–6996 Filed 3–17–97; 9:57 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Office of Attorney Personnel Management

Justice Management Division

Agency Information Collection Activities: Proposed Collection; Reinstatement, Without Change, of a Previously Approved Collection for Which Approval has Expired

ACTION: Application Booklets—Attorney General's Honor Program, Summer Law Intern Program, Law Student Program.

Office of Management and Budget (OMB) approval is sought for the information collection listed below. This proposed information collection was previously published in the **Federal Register** and allowed 60 days for public comment.

The purpose of this notice is to allow an additional 30 days for public comments from the date listed at the top of this page in the **Federal Register**. This process is conducted in accordance with 5 Code of Federal Regulation, Part 1320.10. Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, Attention: Department of Justice Desk Officer, Washington, DC 20503. Additionally, comments may be submitted to OMB via facsimile to 202–395–7285. Comments may also be submitted to the Department of Justice (DOJ), Justice Management Division, Information Management and Security Staff, Attention: Department Clearance Officer, Suite 850, 1001 G Street, NW, Washington, DC, 20530. Additionally, comments may be submitted to DOJ via facsimile to 202–514–1534. Written comments and suggestions from the public and affected agencies should address one or more of the following points:

(1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency/component, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agencies/components estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Overview of this information collection:

(1) Type of information collection: Reinstatement, without change, of a previously approved collection for which approval has expired.

(2) The title of the form/collection: Application Booklets—Attorney General's Honor Program, Summer Law Intern Program, Law Student Program.

(3) The agency form number, if any, and the applicable component of the Department sponsoring the collection. Form number: None. Office of Attorney Personnel Management, Justice Management Division, United States Department of Justice.

(4) Affected public who will be asked or required to respond, as well as a brief abstract. Primary: Individual or households. Other: None. This data collection is the only vehicle for the Department of Justice (DOJ) to hire graduating law students. This application form is submitted voluntarily, submitted only once a year by students/judicial law clerks who will be in this applicant pool only once; and the information sought only relates to the hiring criteria established as an internal matter by DOJ personnel.

(5) An estimate of the total number of respondents and the amount of time estimate for an average respondent to respond: 5,700 respondents at 1 hour per response.

(6) An estimated of the total public burden (in hours) associated with the collection: 5,700 annual burden hours.

Public comment on this proposed information collection is strongly encouraged.

Dated: March 14, 1997.

Robert B. Briggs,

Department Clearance Officer, United States Department of Justice.

[FR Doc. 97–6875 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–24–M

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that by application dated August 8, 1996, and relevant written statements of fact received January 8, 1997, B.I. Chemical, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basis classes of controlled substances listed below:

Drug	Schedule
Methadone (9250)	II
Methadone-intermediate (9254)	II
Levo-alphacetylmethadol (LAAM) (9648).	II

The firm plans to manufacturer the listed controlled substances in bulk for distribution to its parent company for formulation into finished pharmaceuticals.

Any other such applicant and any person who is presently registered with DEA to manufacturer such substances may file comments or objectives to the issuance of the above application.

Any such comments or objections may be addressed, in qunituplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than May 19, 1997.

Dated: February 21, 1997.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 97–6920 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–09–M

Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1311.42 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on May 6, 1996, Glaxo Wellcome Inc., Attn: Jeffrey A. Weiss, 1011 North Arendell Avenue, P.O. Box 1217, Zebulon, North Carolina 27597–2309, made application to the Drug Enforcement Administration to be registered as an importer of remifentanil (9739), which did not become a basic class of controlled substance in Schedule II until November of 1996. Therefore, this application was not processed until remifentanil was controlled and relevant statements of fact dated February 12, 1997, were received.

The remifentanil is being imported for the production of Ultiva dosage forms and for research and new product development.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled substance may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.54 in such form as prescribed in 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than April 18, 1997.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1311.42 (b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745–46 (September 23, 1975), all applicants for registration to import basic classes of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42 (a), (b), (c), (d), (e), and (f) are satisfied.

Dated: March 12, 1997.

Terrance W. Woodworth,

Acting Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 97–6921 Filed 3–18–97; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated October 28, 1996, and published in the **Federal Register** on November 27, 1996 (61 FR 60305), Hoffmann-LaRoche, Inc., 340 Kingsland Street, Nutley, New Jersey 07110, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of levorphanol (9220), a basic class of controlled substance listed in Schedule II.

DEA has considered the factors in Title 21, United States Code, Section 923(a) and determined that the registration of Hoffmann-LaRoche, Inc. to manufacture levorphanol is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. 823 and 28 C.F.R. 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed above is granted.